Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl–expressing human leukemia cells

Warren Fiskus, Michael Pranpat, Purva Bali, Maria Balasis, Sandhya Kumaraswamy, Sandhya Boyapalle, Kathy Rocha, Jie Wu, Francis Giles, Paul W. Manley, Peter Atadja, Kapil Bhalla

Blood (2006) 108 (2): 645–652.

https://doi.org/10.1182/blood-2005-11-4639

Published: 2006

Journal Articles

Histone Deacetylase Inhibitors LBH589 and LAQ824 Deplete Ezh2 and Associated Polycomb Repressive Complex 2/3 Proteins Resulting in Downregulation of HOXA9 and MEIS1 Expression in Human Acute Leukemia Cells.

Warren Fiskus, PhD, Michael Pranpat, MS, Purva Bali, MS, Sandhya Kumaraswamy, PhD, Sandhya Boyapalle, PhD, Kathy Rocha, BS, Maria Balasis, BS, Peter Atadja, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 2482.

https://doi.org/10.1182/blood.V106.11.2482.2482

Published: 2005

Journal Articles

Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells.

Angela Hatter, BS, Purva Bali, MS, Maria Balasis, BS, Warren Fiskus, PhD, Sandhya Boyapalle, PhD, Sandhya Kumaraswamy, PhD, Kathy Rocha, BS, Michael Pranpat, BS, Alison Hannah, MD, Eduardo Sotomayor, MD, PhD, Victoria Richon, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 2418.

https://doi.org/10.1182/blood.V106.11.2418.2418

Published: 2005

Journal Articles

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Sandhya Kumaraswamy, PhD, Que T. Lambert, MS, Kathy Rocha, BS, Purva Bali, MS, Warren Fiskus, PhD, Maria Balasis, BS, Michael Pranpat, MS, Sandhya Boyapalle, PhD, Alison Hannah, MD, Gary W. Reuther, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 4401.

https://doi.org/10.1182/blood.V106.11.4401.4401

Published: 2005

Journal Articles

Co-Treatment with a Novel Heat Shock Protein (hsp) 90 Inhibitor IPI504 and the Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Wild Type or Mutant Bcr-Abl-T315I or FLT-3-ITD-Containing Human Leukemia Cells.

Warren Fiskus, PhD, Purva Bali, MS, Michael Pranpat, MS, Maria Balasis, BS, Sandhya Kumaraswamy, PhD, Sandhya Boyapalle, PhD, Kathy Rocha, BS, Jeffery Tong, MD, Victoria Richon, PhD, Emmanuel Normant, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 4461.

https://doi.org/10.1182/blood.V106.11.4461.4461

Published: 2005

Journal Articles

Increased Levels of the Heat Shock Protein (hsp) 70 Contribute as a Pro-Survival and Pro-Growth Mechanism in the Transformation of Bone Marrow Progenitor Cells.

Sandhya Boyapalle, PhD, Kathy Rocha, BS, Fei Guo, PhD, Purva Bali, MS, Maria Balasis, BS, Warren Fiskus, PhD, Sandhya Kumaraswamy, PhD, Michael Pranpat, MS, Kapil Bhalla, MD

Blood (2005) 106 (11): 1374.

https://doi.org/10.1182/blood.V106.11.1374.1374

Published: 2005

NARROW

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl–expressing human leukemia cells

Histone Deacetylase Inhibitors LBH589 and LAQ824 Deplete Ezh2 and Associated Polycomb Repressive Complex 2/3 Proteins Resulting in Downregulation of HOXA9 and MEIS1 Expression in Human Acute Leukemia Cells.

Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells.

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Co-Treatment with a Novel Heat Shock Protein (hsp) 90 Inhibitor IPI504 and the Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Wild Type or Mutant Bcr-Abl-T315I or FLT-3-ITD-Containing Human Leukemia Cells.

Increased Levels of the Heat Shock Protein (hsp) 70 Contribute as a Pro-Survival and Pro-Growth Mechanism in the Transformation of Bone Marrow Progenitor Cells.

Email alerts

ASH Publications

American Society of Hematology

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl–expressing human leukemia cells

Histone Deacetylase Inhibitors LBH589 and LAQ824 Deplete Ezh2 and Associated Polycomb Repressive Complex 2/3 Proteins Resulting in Downregulation of HOXA9 and MEIS1 Expression in Human Acute Leukemia Cells.

Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells.

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Co-Treatment with a Novel Heat Shock Protein (hsp) 90 Inhibitor IPI504 and the Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Wild Type or Mutant Bcr-Abl-T315I or FLT-3-ITD-Containing Human Leukemia Cells.

Increased Levels of the Heat Shock Protein (hsp) 70 Contribute as a Pro-Survival and Pro-Growth Mechanism in the Transformation of Bone Marrow Progenitor Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only